Vancouver, BC – Medipure Holdings Inc. is taking another step to advance its research and development by creating a subsidiary, Medipure d.o.o., in Croatia.
The Croatian R&D facility will focus on clinical trials and pharmacology. Along with full analytical labs, this site will house a GMP facility allowing the Company to produce drugs in compliance with the European regulatory standards necessary to support clinical trials on the road to regulatory approvals and commercialization.
The European Union has taken steps to create an environment to attract global preclinical studies. It is important to note that clinical trials comply with international standards set by EU, Health Canada and the FDA.
Medipure’s research is focused on the body’s endocannabinoid system, a previously under-explored network of receptors throughout the body that plays a role in many biological and physiological functions. It’s focused on the development of a safe and non-addictive prescription drug line to address chronic pain, anxiety and a variety of other conditions. The drug formulations could be an economical, non-addictive alternative to opioid and benzodiazepine-based prescription drugs that can be highly addictive with life-altering side effects.
For more information, please visit: http://medipurepharmaceuticals.com